Aemetis is a renewable fuels and biochemicals holding company. Through its subsidiaries, the company focuses on the production of renewable fuels and chemicals that replace petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. The company's reportable geographic segments include: North America, which includes its ethanol production facility in Keyes, CA and produces denatured fuel ethanol, wet distillers grains, distillers corn oil, and condensed distillers solubles; and India, which includes its biodiesel manufacturing plant in Hyderabad, India and has biodiesel and refined glycerin.

Amcor is a packaging company. Co. has the following reportable segments: Amcor Rigid Plastics, which manufactures rigid plastic containers for a range of primarily beverage and food products; Amcor Flexibles, which represents the aggregation of four operating segments of which each manufactures flexible and film packaging for their respective industries; as well as Other/Investments, which holds Co.'s equity accounted investments in the associate AMVIG Holdings Limited (AMVIG) and the joint venture Discma AG (Discma). AMVIG is mainly involved in the manufacture of tobacco packaging while Discma's operations primarily relate to the development and licensing of packaging product development.

Blue Apron provides recipes, ingredients, and cooking techniques. The company's products include: meals, which consist of a Two-Serving Plan that serves two people, and a Family Plan that serves four people; wine, through Blue Apron Wine delivery service to deliver wines, including red and white wines (and roses, depending on the season), tasting notes, pairing tips, and the story behind each wine; market, which features a selection of cooking tools, utensils, and pantry items through its e-commerce marketplace, Blue Apron Market; and digital experience, which provides how-to cooking videos, stories about its suppliers, and its collection of various recipes that customers can access on their own.

Calumet Specialty Product Partners is a holding company. Through its subsidiaries, the company is an independent producer of hydrocarbon products in North America. In its specialty products segment, the company processes crude oil and other feedstocks into a variety of customized lubricating oils, white mineral oils, solvents, petrolatums and waxes. The company's specialty products are sold to customers who purchase them as raw material components for basic industrial, consumer and automotive goods. In its fuel products segment, the company processes crude oil into fuel and fuel-related products, including gasoline, diesel, jet fuel, asphalt and heavy fuel oils, and resells purchased crude oil to third party customers.

Celldex Therapeutics is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has four drug candidates in clinical development, including CDX-1140, an agonist human monoclonal antibody targeted to CD40, a key activator of immune response; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3; varlilumab, an immune modulating antibody targeting CD27 designed to improve a patient's immune response; and CDX-301, a dendritic cell growth factor.

Centrus Energy is a supplier of nuclear fuel and services for the nuclear power industry. The company operates two business segments: low-enriched uranium (LEU), which supplies various components of nuclear fuel to utilities; and contract services, which provides engineering, design, and manufacturing services to government and private sector customers. The company's LEU business involves the sale of low-enriched uranium, its components, and natural uranium to utilities operating commercial nuclear power plants. LEU is a component in the production of nuclear fuel for reactors that produce electricity. The company supplies LEU to both domestic and international utilities for use in nuclear reactors.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company's clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure, AMG 594, a cardiac troponin activator, reldesemtiv, a skeletal muscle troponin activator for the treatments of spinal muscular atrophy and amyotrophic lateral sclerosis, and CK-3773274, a cardiac myosin inhibitor which is designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy.

Evolent Health is a holding company. Through its subsidiaries, the company is a managed care services firm that supports health systems and physician organizations in their migration toward care and population health management. The company's Services segment provides its customers, who it refers to as partners, with a population health management platform, integrated data and analytics capabilities, claims processing services, including pharmacy benefit management, specialty care management services and health plan administration services. The company's subsidiary, True Health New Mexico, Inc. is a physician-led health plan in New Mexico available via the commercial market for employer-sponsored health coverage.

Full House Resorts owns, leases, operates, develops, manages, and/or invests in casinos and related hospitality and entertainment facilities. The company manages its casinos based on geographic regions within the U.S. The casino/resort operations includes four segments: the Silver Slipper Casino and Hotel (Hancock County, MI); Bronco Billy's Casino and Hotel (Cripple Creek, CO); the Rising Star Casino Resort (Rising Sun, IN); and the Northern Nevada segment, consisting of the Grand Lodge Casino (Incline Village, NV) and Stockman's Casino (Fallon, NV).

Innodata is a data engineering company. The company has three segments: Digital Data Solutions, which provides a range of solutions and platforms for solving complex data challenges that companies face; Synodex, which provides an intelligent data platform that transforms medical records into useable digital data organized in accordance with its proprietary data models or client data models; and Agility Segment, which provides an intelligent data platform that provides marketing communications and public relations personnel with the ability to target and distribute content to journalists and social media influencers and to monitor and analyze global news channels and social media channels.

IVERIC bio is a biopharmaceutical company focused on the discovery and development of treatment options for retinal diseases with unmet medical needs. The company is developing both therapeutics for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. The company's product candidate Zimura, a complement inhibitor, is a chemically-synthesized, pegylated RNA aptamer. The company's clinical trials for Zimura include: OPH2003, for patients with geographic atrophy secondary to dry age-related macular degeneration; and OPH2005, for the treatment of Stargardt disease.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's pipeline consists of two clinical-stage product candidates, maralixibat and volixibat, with mechanisms of action that have potential utility across a wide range of orphan liver diseases.

Natural Gas Services Group is a provider of natural gas compression services and equipment to the energy industry. The company manufactures, fabricates, rents, sells and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. The company's operating units include: Rental, which provides small, medium and large horsepower applications for oil and natural gas production; Engineered Equipment Sales, which includes compressor fabrication, parts sales and compressor rebuilds, flare fabrication, and compressor manufacturing; and Service and Maintenance, which services and maintains compressors owned by its customers on an as needed and contract basis.

OptimizeRx is a digital health company. The company provides electronic clinical information via electronic health record companies. The company's principal products and applications include: financial messaging, which is a virtual Patient Support Center that allows doctors and staff to access sample vouchers, co-pay coupons and other patient support through their EMR and/or e-Prescribe systems to search, print or electronically dispense directly; brand and clinical messaging, which includes a variety of brand awareness and clinical messaging services that can be tailored; and digital therapeutics, which consist of delivering patient programs with treatment and affordability information, and among others.

RADCOM provides innovative service assurance and customer experience management solutions for telecom operators and communications service providers. Co. specializes in solutions for next-generation mobile and fixed networks, including LTE, VoLTE, IMS, VoIP, UMTS/GSM and mobile broadband. Co.'s comprehensive, carrier-grade solutions are designed for big data analytics on terabit networks, and are used to prevent service provider revenue leakage and to enhance customer care management. Co.'s products interact with policy management to provide self-optimizing network solutions. Co.' s products and solutions consist of the MaveriQ Service Assurance and Customer Experience Management solution.

Safe Bulkers is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along worldwide shipping routes for consumers of marine drybulk transportation services. As of Feb. 9, 2018, Co. had a fleet of 39 drybulk vessels, with an aggregate carrying capacity of 3,513,800 dwt and an average age of 7.6 years. Co. deploys its vessels on both period time charters and spot time charters. The vessels on period time charters provide Co. with relatively stable cash flow and utilization rates, while the vessels in the spot market allow Co. to maintain its flexibility in low charter market conditions.

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of diseases. The company is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies, Mucopolysaccharidosis type IIIA and other neuromuscular and central nervous system. The company's commercial product, EXONDYS 51? (eteplirsen) Injection is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

TransMedics is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company developed the Organ Care System ("OCS") to replace a decades-old standard of care. The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. The company's OCS technology replicates many aspects of the organ's natural living and functioning environment outside of the human body.